Hook & thesis
ResMed (RMD) has been dinged in recent sessions, but this pullback is more panic than pivot. The stock sits at $198.47 today after sliding from its 52-week high of $293.81; yet the business underneath remains high-quality: double-digit revenue growth, healthy margins, strong free cash flow and a clean balance sheet. That combination gives us a margin-of-safety opportunity to buy a leader in sleep and respiratory care at an attractive entry.
My trade idea: enter at $188.00, place a stop loss at $176.00, and target $238.00 over a mid-term window (45 trading days). This setup captures upside if markets re-rate growth names and gives room for short-term noise to wash out while keeping a defined downside.
What ResMed does and why it matters
ResMed manufactures and sells cloud-connected devices and digital health software focused on sleep-disordered breathing, COPD and other chronic respiratory conditions. It operates through two segments: Sleep and Respiratory Care and Software as a Service. The company now distributes products in 140+ countries, and it is pushing deeper into chronic-care management through SaaS offerings and selective M&A (for example, the Noctrix Health acquisition announced on 06/03/2026 for $340 million).
Why investors should care: demographic and healthcare trends favor ResMed. The sleep-apnea device market is forecast to grow mid-single digits to high-single digits annually as diagnosis, homecare and telemedicine expand. For ResMed specifically, the combination of device sales and recurring-software revenues increases stickiness and visibility into future cash flow.
Fundamentals: the numbers that matter
- Recent quarter strength: ResMed reported Q2 FY2026 sales of $1.42 billion, up 11% year-over-year, and adjusted EPS of $2.81 (beat consensus of $2.72) - evidence the business is still compounding revenue and margin.
- Valuation: the stock trades at roughly 19x trailing earnings (P/E ≈ 19.1-19.3 in the data) with a market capitalization near $28.8 billion.
- Cash flow and balance sheet: free cash flow was $1.754 billion, which implies an FCF yield around 6.1% relative to the $28.8 billion market cap (1.754 / 28.789 ≈ 6.1%). Debt-to-equity is low at ~0.10, giving the company balance-sheet optionality for M&A, buybacks, or cushioning in the event of headwinds.
- Shareholder returns: the company pays a $0.60 annual dividend per share (quarterly), yielding about 1.2% at current prices.
Technical and market context
From a technical viewpoint, RMD is trading below its 50-day moving average (SMA 50 ≈ $203.11 and EMA 50 ≈ $203.77) but above shorter-term averages (10-day SMA ≈ $193.51, 20-day SMA ≈ $192.60). Momentum indicators are mixed-to-favorable: RSI sits near 51.7 (neutral) while the MACD histogram shows bullish momentum. Importantly, short interest has been meaningful (recent settlement 06/15/2026: ~12.9 million shares, days-to-cover ≈ 9), and June short-volume prints show elevated short participation in intraday flows - a potential catalyst if sentiment flips.
Valuation framing
At roughly 19x trailing earnings and with an FCF yield north of 6%, ResMed's current valuation offers a relative safety buffer compared with prior multiples when the stock was trading well above $250. The company’s return-on-equity (≈23.4%) and return-on-assets (≈17.3%) show high capital efficiency. With low leverage (debt/equity ≈0.10) and recurring SaaS revenue building, the intrinsic business looks robust enough to merit a premium - but the market has already repriced some of that premium. This is a classic quality-growth name trading at a more reasonable multiple after a fear-driven move lower.
Catalysts that could drive the trade
- Quarterly earnings beat or guidance raise (next quarterly release) that reaffirms the 11%+ revenue growth trajectory and double-digit EPS growth commentary management provided earlier in the year.
- Integration or commercialization progress from the Noctrix Health acquisition (announced 06/03/2026) - successful early adoption of the Nidra therapy into ResMed’s ecosystem would validate M&A upside and product diversification.
- Clarification on Medicare reimbursement or regulatory signals that remove policy-driven uncertainty; any positive commentary from payors or regulators would be a tailwind.
- Short-covering spike: with elevated short interest and high short-volume days in June, an episodic squeeze remains a plausible technical catalyst if market sentiment inflects.
Trade plan
| Entry | Stop | Target | Horizon |
|---|---|---|---|
| $188.00 | $176.00 | $238.00 | Mid term (45 trading days) |
Rationale: $188 is below the current print and offers a ~5%+ buffer beneath today’s price while still being above the 52-week low of $180.27. The stop at $176 keeps risk limited to a clear downside break; $176 is outside typical intraday noise and below recent support levels. The target $238 reflects a ~26.6% move from the $188 entry and would be a partial re-rating toward cycle highs without requiring a full return to the 52-week top. Expect to hold the position for up to 45 trading days to let catalysts play out and allow volatility to subside.
Risks and counterarguments
- Reimbursement/regulatory squeeze - Medicare reimbursement uncertainty or adverse regulatory changes could hit device pricing and adoption rates and compress near-term margins. This is a recurring headline risk for medical device names.
- Competition and technology disruption - rivals developing new, less-invasive or lower-cost therapies for sleep apnea and respiratory care could erode market share or pricing power, pressuring long-run revenue growth.
- Execution on software and M&A integration - the Noctrix acquisition and SaaS expansion are strategic positives but carry execution risk. Failure to commercialize new therapies or integrate purchases could dilute returns.
- Macroeconomic/interest-rate pressure - as a growth-at-a-premium stock, RMD is vulnerable to multiple compression in risk-off market regimes or if rates re-price growth assets lower.
- Technical risk from high short interest - while a short-covering event can be a catalyst to the upside, sustained heavy short selling can also compound downside if negative news arrives; days-to-cover near 9 means short trades are material and can amplify moves.
Counterargument to the thesis: It’s reasonable to argue the market is correctly discounting longer-term headwinds. If Medicare reimbursement trends worsen or a competing treatment meaningfully reduces CPAP adoption, ResMed’s premium multiples could be hard to sustain and shares could revisit the lower end of the range. In that scenario, the $188 entry would not be safe enough and the stop at $176 would be hit — underscoring the importance of strict risk management.
Why this is a margin-of-safety trade, not a blind gamble
Three elements define the margin of safety here: (1) tangible cash generation - $1.75B in FCF gives concrete valuation support; (2) low leverage - debt/equity ≈0.10 provides financial flexibility; and (3) recurring SaaS revenue that improves revenue quality and visibility. Combined, these factors reduce downside risk compared with more speculative names trading at similar P/Es but without durable cash flows.
What would change my mind
I would abandon this trade if any of the following occur: management materially lowers guidance, Q3 results miss consensus and show deteriorating margins, new regulatory rulings cut reimbursement materially, or cash flow generation weakens meaningfully below the current free cash flow run-rate. Conversely, I would add to the position if ResMed reports sustained double-digit organic revenue growth coupled with margin expansion and management signals an acceleration in SaaS ARR visibility.
Bottom line
ResMed’s pullback creates a disciplined opportunity to buy a high-quality medical device and digital-health franchise with tangible free cash flow and a conservative balance sheet. The proposed entry at $188 with a $176 stop and $238 target across a 45-trading-day horizon balances upside potential with clearly defined downside protection. This is a mid-term, risk-managed trade for investors who believe durable demand for sleep and respiratory solutions will persist and who want to capitalize on short-term fear without sacrificing fundamental discipline.
Selected data points (for reference)
- Current price: $198.47
- Market cap: $28.79B
- Trailing P/E: ~19x
- Free cash flow: $1.754B (FCF yield ≈ 6.1%)
- Q2 FY2026 sales: $1.42B, +11% YoY; adj. EPS: $2.81
- 52-week range: $180.27 - $293.81
- Dividend: $0.60 annual ($0.15 quarterly), yield ≈ 1.2%